Page last updated: 2024-12-08

dialuric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dialuric acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dialuric acid : A member of the class of barbiturates that is barbituric acid in which a hydrogen attached to a ring carbon is replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID179547
CHEBI ID76452
SCHEMBL ID133284
MeSH IDM0045871

Synonyms (22)

Synonym
dialuric acid
2,4,5,6-pyrimidinetetrol
5-hydroxybarbituric acid
BB 0262114
5-HYDROXY-HEXAHYDRO-PYRIMIDINE-2,4,6-TRIONE
5-hydroxy-2,4,6(1h,3h,5h)-pyrimidinetrione
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-hydroxy-
5-hydroxy-1,3-diazinane-2,4,6-trione
444-15-5
AKOS006230288
FT-0620479
SCHEMBL133284
5-hydroxypyrimidine-2,4,6(1h,3h,5h)-trione
CHEBI:76452
5-alloxanol
5-hydroxy-2,4,6(1h,3h,5h)-pyrimidinetrione #
BVEWMNTVZPFPQI-UHFFFAOYSA-N
Q27145999
DTXSID601265223
mfcd00055405
dialuricacid-13c,15n2
T856T7DXN9

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Here, the toxic effects of dialuric acid targeting MAPT through in silico computational predictions have been investigated."( A system-level approach to investigate alloxan-induced toxicity in microtubule-binding protein to lead type 2 diabetes mellitus.
Kannan, ND; Sathish Kumar, P, 2021
)
0.92

Dosage Studied

ExcerptRelevanceReference
" Alloxan-zinc-chelate protractedly and significantly made the blood sugar's increase up to the 7th d post injectionem, without being able to maintain a permanent hyperglycemia with half-normal dosage in comparison with alloxan."( [Effect of alloxans on pancreatic B-cells with special regard to the alloxan-metal-complex theory. I. Effects of alloxan, alloxan-zinc chelates, dilauric acid and colchicine on blood sugar and rate of mitosis of B-cell Langerhans islets].
Glass, P; Müller, H; Schmidt, R; Schneider, S; Unger, E, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
5,6-dimethylbenzimidazole biosynthesis I (aerobic)311
adenosylcobalamin biosynthesis from cobyrinate a,c-diamide II029
adenosylcobalamin biosynthesis II (aerobic)060

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (63.46)18.7374
1990's9 (17.31)18.2507
2000's9 (17.31)29.6817
2010's0 (0.00)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.49 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index79.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other58 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]